From a new article
in the New York Times:New antiviral drugs are startlingly effective against the coronavirus—if they’re taken in time.
n March, 2020, researchers at Emory University published a paper about a molecule called NHC/EIDD-2801. At the time, there were no treatments available for the coronavirus. But NHC/EIDD-2801, the researchers wrote, possessed “potency against multiple coronaviruses,” and could become “an effective antiviral against SARS-CoV-2.” A few days later, Emory licensed the molecule to Ridgeback Biotherapeutics, a Miami-based biotechnology company which had previously developed a monoclonal antibody for Ebola. Ridgeback partnered with the pharmaceutical giant Merck to accelerate its development.
The Emory researchers named their drug molnupiravir, after Mjölnir—the hammer of Thor. It turns out that this was not hyperbole. Last month, Merck and Ridgeback announced that molnupiravir could reduce by half the chances that a person infected by the coronavirus would need to be hospitalized. The drug was so overwhelmingly effective that an independent committee asked the researchers to stop their Phase III trial early—it would have been unethical to continue giving participants placebos. None of the nearly four hundred patients who received molnupiravir in the trial went on to die, and the drug had no major side effects. On November 4th, the U.K. became the first country to approve molnupiravir; many observers expect that an emergency-use authorization will come from the U.S. Food and Drug Administration in December.
Oral antivirals like molnupiravir could transform the treatment of covid-19, and of the pandemic more generally. Currently, treatments aimed at fighting covid—mainly monoclonal antibodies and antiviral drugs like remdesivir—are given through infusion or injection, usually in clinics or hospitals. By the time people manage to arrange a visit, they are often too sick to receive much benefit. Molnupiravir, however, is a little orange pill. A person might wake up, feel unwell, get a rapid covid test, and head to the pharmacy around the corner to pick up a pack. A full course, which needs to start within five days of the appearance of symptoms, consists of forty pills—four capsules taken twice a day, for five days. Merck is now testing whether molnupiravir can prevent not just hospitalization after infection but also infection after exposure. If that’s the case, then the drug might be taken prophylactically—you could get a prescription when someone in your household tests positive, even if you haven’t.
Molnupiravir is—and is likely to remain—effective against all the major coronavirus variants. In fact, at least in the lab, it works against any number of RNA viruses besides sars-CoV-2, including Ebola, hepatitis C, R.S.V., and norovirus. Instead of targeting the coronavirus’s spike protein, as vaccine-generated antibodies do, molnupiravir attacks the virus’s basic replication machinery. The spike protein mutates over time, but the replication machinery is mostly set in stone, and compromising that would make it hard for the virus to evolve resistance. Once it’s inside the body, molnupiravir breaks down into a molecule called NHC. As my colleague Matthew Hutson explained, in a piece about antiviral drugs published last year, NHC is similar to cytosine, one of the four “bases” from which viral RNA is constructed; when the coronavirus’s RNA begins to copy itself, it slips into cytosine’s spot, in a kind of “Freaky Friday” swap. The molecule evades the virus’s genetic proofreading mechanisms and wreaks havoc, pairing with other bases, introducing a bevy of errors, and ultimately crashing the system.
With winter approaching, America is entering another precarious moment in the pandemic. Coronavirus cases have spiked in many European countries—including some with higher vaccination rates than the U.S.—and some American hospitals are already starting to buckle under the weight of a new wave. Nearly fifty thousand Americans are currently hospitalized with covid-19. It seems like molnupiravir is arriving just when we need it.
It isn’t the only antiviral covid pill, either. A day after the U.K. authorized Merck’s drug, Pfizer announced that its antiviral, Paxlovid, was also staggeringly effective at preventing the progression of covid-19 in high-risk patients. The drug, when taken within three days of the onset of symptoms, reduced the risk of hospitalization by nearly ninety per cent. Only three of the nearly four hundred people who took Paxlovid were hospitalized, and no one died; in the placebo group, there were twenty-seven hospitalizations and seven deaths. Paxlovid is administered along with another antiviral medication called ritonavir, which slows the rate at which the former drug is broken down by the body. Like Merck, Pfizer is now examining whether Paxlovid can also be used to prevent infections after an exposure. Results are expected early in 2022. (It’s not yet known how much of a difference the drugs will make for vaccinated individuals suffering from breakthrough infections; Merck’s and Pfizer’s trials included only unvaccinated people with risk factors for severe disease, such as obesity, diabetes, or older age. Vaccinated individuals are already much less likely to be hospitalized or die of covid-19.)

News
How can Nanotechnology be Used to Reverse Skin Aging?
Although skin aging has not been related to many health complications, it has aesthetic issues. Some of the common symptoms of skin aging are changes in the skin texture (rough, dry, and itchy), discoloration, [...]
Emission of Fe- and Ti-Containing Nanoparticles from Coal-Fired Power Plants
In an article published in the journal Science of the Total Environment, researchers have highlighted the significance and potential risks associated with the release of nanoparticles from coal-fired power plants. Applying the single-particle inductively coupled plasma mass [...]
Covalent Organic Framework Nanofluidic Hybrid Membrane for Osmotic Energy Generation
A paper recently published in the journal ACS Applied Energy Materials demonstrated the feasibility of using a covalent organic framework (COF)-based nanofluidic hybrid membranes (NHMs) to attain enhanced interfacial ion transport for the generation of osmotic [...]
Degradable Nanocomposite Removes Antibiotics from Contaminated Water
The excess fluoroquinolones (FQs) discharged into the aquatic environment due to human activities must be removed cost-effectively. In an article published in the Journal of Cleaner Production, the authors fabricated an environment-friendly dealkaline lignin-grafted Fe3O4 nanoparticles [...]
Light-controlled reactions at the nanoscale
Controlling strong electromagnetic fields on nanoparticles is the key to triggering targeted molecular reactions on their surfaces. Such control over strong fields is achieved via laser light. Although laser-induced formation and breaking of molecular [...]
Bright Future for Nanophotonic Chips with Topological Rainbow Device
A paper recently published in the journal Nature Communications demonstrated an effective method to realize on-chip nanophotonic topological rainbow devices using the concept of synthetic dimensions. Importance of Synthetic Dimensions for the Construction of Topological Nanophotonics [...]
Green Approach to Silver Nanoparticle Fabrication with Citrus Fruits
In a study available in the journal Materials Today: Proceedings, silver nanoparticles (Ag NPs) were fabricated using a green method using Citrus X sinensis. Methylthioninium Chloride (MB) Dyes Threatening the Environment Dye and sewage drainage into [...]
Coronavirus ‘ghosts’ found lingering in the gut
Scientists are studying whether long COVID could be linked to viral fragments found in the body months after initial infection. In the chaos of the first months of the coronavirus pandemic, oncologist and geneticist [...]
Experts perplexed over number of people getting long COVID
Public health experts are divided over how many people are getting long COVID-19, a potentially debilitating condition that comes after a patient has recovered from the coronavirus. Ill effects from the condition can include [...]
Four strange COVID symptoms you might not have heard about
Well over two years into the pandemic, hundreds of thousands of COVID cases continue to be recorded around the world every day. With the rise of new variants, the symptoms of COVID have also evolved. Initially, [...]
A new method for exploring the nano-world
Nanoparticles are everywhere. They are in our body as protein aggregates, lipid vesicles, or viruses. They are in our drinking water in the form of impurities. They are in the air we breath as [...]
Breast Cancer Drug Resistance Tackled By Polymer Nanoparticles
Drug resistance is a common phenomenon, with drugs becoming less and less effective as their usage increases. To address this issue, a novel technique employing conjugated polymer-based nanoparticles is presented in the study published [...]
New imaging method makes microrobots visible in the body
Microrobots have the potential to revolutionize medicine. Researchers at the Max Planck ETH Centre for Learning Systems have now developed an imaging technique that for the first time recognises cell-sized microrobots individually and at [...]
Multifunctional Nanocrystals Enhance Cancer Cell Killing Therapies
Scientists have recently developed multifunctional hexagonal NaxWO3 nanocrystals that can serve as microwave sensitizers to kill cancer cells as well as improve the overall chemodynamic therapy (CDT). This study is available as a pre-proof in Chemical Engineering Journal. [...]
Biotech, nanomedicine, and AI combine for health breakthrough predicted by Apple genius Steve Jobs
Apple’s visionary founder, the late Steve Jobs once said, “the biggest innovations of the 21st century will be at the intersection of biology and technology”. And that prediction is coming true in the drug [...]
Making chemical separation more eco-friendly with nanotechnology
Chemical separation processes are essential in the manufacturing of many products from gasoline to whiskey. Such processes are energetically costly, accounting for approximately 10–15 percent of global energy consumption. In particular, the use of [...]